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Background: Multiple studies proved that miRNAs have a causal role in tumorigenesis. Some miRNAs are regulated
by epigenetic alterations in their promoter regions and can be activated by chromatin- modifying drugs.
Methods: We treated cervical cancer cells with 5-aza-2’-deoxycytidine and get a microarray analysis. Dysregulation
of miRNAs was measured by qPCR in cervical cell lines and methylation status of them in cervical cancer tissue
were performed with MeDIP-qPCR assay.
Results: We found hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have
some relationship with HPV infection in cervical cell lines. In primary tumors of cervix with paired normal tissue,
expression levels of miRNAs were inversely correlated with their DNA methylation status in the cervical cancer cell
lines treated with 5-AZA.
Conclusions: Our results indicate that miRNAs might play a role in the pathogenesis of human cervical cancer with
HPV and identify altered miRNA methylation as a possible epigenetic mechanism involved in their aberrant
expression.
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Cervical cancer is the second most common cancer in
women worldwide. Approximately 80% of primary cer-
vical cancers arise from pre-existing squamous dysplasia.
The most important etiologic agent in the pathogenesis
is human papillomavirus (HPV). However, not all
women infected with high-risk HPV develop cervical
carcinoma. It is obviously that many genetic and epige-
netic alternations occur during its tumorigenesis. Among
those changes, aberrant promoter methylation of tumor-
suppressor genes gives rise to its silencing functions and
results in the significant carcinogenesis of cervical
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reproduction in any medium, provided the orUntil recently, few evidences have shown that miRNA
genes may be regulated by epigenetic mechanisms, as
changes in genomic DNA methylation pattern. In this
study, we present the results of a genome-wide miRNA
expression in cervical cancer cells treated with 5-aza-2’-
deoxycytidine and identify the altered methylation of
miRNA genes as a possible epigenetic mechanism respon-
sible for their aberrant expression.Material and methods
Cell culture
Four human cervical carcinoma cell lines (C33A, Hela,
CaSki and SiHa) were obtained from the American Type
Culture Collection (Manassas, VA) and cultured in
DMEM supplemented with 10% fetal bovine serum
(Invitrogen) at 37°C and 5% CO2 in a humidified incuba-
tor. The Caski line was reported to contain an integrated
human papillomavirus type 16 genome (HPV-16, about
600 copies per cell) as well as sequences related to HPV-. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to contain an integrated human papillomavirus type 16
genome (HPV-16, 1 to 2 copies per cell) (Bishop JA,
et al., [2]). Hela cell contains an integrated HPV-18 genome
(Iwakawa R, et al., [3]), while C33A contains no HPV
(Hwang CF, et al., [4]).
Clinical samples
Fifty histopathologically verified cervical tumor samples
and matched normal tissues were obtained from pa-
tients, who were admitted to the Department of Gyneco-
logic Oncology of Sun Yat-sen Memorial Hospital, Sun
Yat-sen University. The tissues were snap frozen in li-
quid nitrogen immediately after surgical removal and
stored at −80°C until required. None of the patients
recruited into the present study received radiotherapy or
chemotherapy. All of them were tested using the
HybriBio Human Papillomavirus GenoArray Test Kit
(Liu SS, et al., [5]) and infection of HPV-16 or 18 was
confirmed upon hospital admission. Adjacent normal
tissue samples were taken at least 1 cm distal to tumor
margins.
Demethylating experiment
Cervical cancer cells (2×104/well) were allowed to grow
in 6-well plates 48 h before treatment with 10 μmol/L 5-
aza-2’-deoxycytidine (5-AZA; Sigma). After 24 h of treat-
ment, cells were collected and total RNA was isolated
using Trizol reagent. Three replicates for both untreated
cells and 5-AZA–treated cells were used to evaluate the
miRNA expression by microarray profiling. Differentially
expressed miRNAs were identified by using univariate
two-class t test with random variance model.
miRNA microarray hybridization and quantification
Total RNA isolation was done with Trizol (Invitrogen)
according to the manufacturer’s instructions. Using
miRCURY LNA Array (version 11.0) system, RNA sam-
ples were labeled with the Exiqon miRCURY Hy3/Hy5
power labeling kit and hybridized on the miRCURY
LNA Array (version 11.0) station. Hybridization signals
were detected with streptavidin-Alexa Fluor 647 conju-
gate and scanned images (Axon 4000B) were quantified
using the GenePix 6.0 software (Axon Instruments) to
read image raw intensity. The intensity of the green sig-
nal was calculated after background subtraction, and
replicated spots on the same slide were averaged to ob-
tain median intensity. The median normalization
method was used to acquire normalized data (fore-
ground minus background divided by median). The
median was the 50th percentile of miRNA intensity and
was >50 in all samples after background correction. The
threshold value for significance used to define upregulation
or downregulation of miRNAs was a fold change >1.5, witha value of P<0.05 calculated by the t test. Differentially
expressed miRNAs were identified by using the t test pro-
cedure within significance analysis of microarrays (SAM)
(Tusher VG, et al., [6]). The miRNAs selected for investiga-
tion in our study were further filtered on the basis of
expression levels and previously published data.Quantitative real-time PCR
The RT reaction used MMLV reverse transcriptase (Epi-
center, Madison, WI). Quantitative PCR was performed
by an ABI PRISM7500 system (Applied Biosystems,
Foster City, CA). Selected miRNAs were further quanti-
fied with TaqMan quantitative RT-PCR.All reactions
were done in a 20 μL reaction volume in triplicate by
SYBR Green Real-time PCR Universal Reagent
(GenePharma Co., Ltd.) and analyzed by MX-3000P
Real-time PCR machine (Stratagen). Standard curves
were generated and the relative amount of miRNA was
normalized to U6 snRNA (2−ΔCt). Expression fold-
change was evaluated using 2−ΔΔCt. Let-7a was used as
control. Primers were as follows (Additional file 1:
Table S1).Methyl-DNA immunoprecipitation–qPCR
MiRNAs from patients were prepared by overnight pro-
teinase K treatment, phenol–chloroform extraction,
ethanol precipitation, and RNase digestion. Following
denaturation, miRNAs were incubated overnight at 48°C
with 8 micrograms of 5-methylcytidine monoclonal anti-
body (Eurogentec). Fifty microliters of rabbit anti-IgG
magnetic beads (BioLabs S1430S) was added and incu-
bated for 2 h at 48°C,. Magnetic beads–monoclonal anti-
body complexes were sequentially washed by gentle
mixing at 48°C for 4 min with 1 microgram of wash buf-
fer 1 (2 mM EDTA, 20 mM Tris [pH¼8.0], 1% Triton X-
100, 0.1% sodium dodecyl sulfate [SDS], 150mMNaCl),
wash buffer 2 (2 mM EDTA, 20 mM Tris [pH¼8.0], 1%
Triton X- 100, 0.1% SDS, 500 mM NaCl), and wash buf-
fer 3 (1 mM EDTA, 10 mM Tris [pH¼8.0]). After wash-
ing, the complexes were subjected to magnetic
separation rack for 10 min at 48°C, and then elution was
performed with 400 microlitre elution buffer (50 mM
Tris–HCl [pH 8.0], 10 mM EDTA [pH 8.0], 1% SDS).
The elution fraction was subjected to phenol–chloro-
form extraction and ethanol precipitation. The quantity
of immunoprecipitated miRNA was checked with a
Nanodrop spectrophotometer (Agilent) (Liu BL et al.,
[7]; Zhang Y, et al., [8]). PCR amplification using the
real-time PCR was performed as described above. Rela-
tive enrichment of miRNA methylation for each gene
was determined by the same method described above.
The PCR primers used for each gene in this analysis are
given in Additional file 2: Table S2.
Figure 1 Hierarchical cluster tree of representation miRNAs in
cell lines before and after treatment with the demethylating
agent 5-AZA. Each row represented a miRNA and each column
represented a sample. The miRNA clustering tree was shown on the
left, and the sample clustering tree appeared at the top. The color
scale shown at the top illustrated the relative expression level of a
miRNA: red color represented a high expression level; green color
represented a low expression level. The clustering was performed on
differentially expressed miRNAs (differentially expressed in all 4
comparisons); the low intensity expressed miRNAs were filtered
(which ForeGround- BackGround intensities were all <50 in all the
samples). (A1: C33A treated with 5-AZA;A2: C33A; C1: Caski treated
with 5-AZA; C2: Caski; H1: Hela treated with 5-AZA; H2: Hela; S1: Siha
treated with 5-AZA; S2:Siha).
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All database searches were carried out by Ethics com-
mittee of Sun Yat-sen Memorial Hospital, Sun Yat-sen
University(IRB of Sun Yat-sen Memorial Hospital 2012
[03]). Patient data were kept to a minimum and stored
in a secure manner on a database under the control of
the University of Sun Yat-Sen to which only the corre-
sponding author has access.
Statistical analysis
Quantitative data are shown as mean values standard de-
viation. Statistical analyses were performed using




Hierachical clustering analyses of miRNA expression
showed significant changes (>1.5-fold difference) in ex-
pression levels (the resulting hierarchical cluster tree is
reported in (Figure 1). The heat map diagram showed
the result of the two-way hierarchical clustering of genes
and samples. Compared with control, there were 172
miRNAs upregulated and 192 miRNAs down-regulated
in C33A, 40 miRNAs upregulated and 138 miRNAs
down-regulated in Caski, 207 miRNAs upregulated and
103 miRNAs down-regulated in Hela, 231 miRNAs
upregulated and 271 miRNAs down-regulated in Siha
(Additional file 3: Table S3 and Additional file 4: Table S4).
MiR-432, miR-1286, miR-641, miR-1290, miR-1287 and
miR-95 were found up-modulated in Caski, Hela and Siha
but not in C33A induced on treatment, while miR-625 was
down-modulated.
The R-value was calculated after array normalization
using the Median method. When two samples were dif-
ferent, the correlation coefficient R of them did not
mean the reproducibility of the slides but the difference
of samples. When two samples were the same, the
Figure 2 Correlation R-value in the Correlation & Scatter Plot. The data represented the change of miRNA profiling before (x axis) and after
(y axis) the 5-AZA treatment in different tumor cells (Up left: C33A, Up right: Caski, low left: Hela, low right: Siha). The red lines in the panals
represented the threshold of upregulation,while green lines represented the threshold of downregulation of miRNA expression.
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bility of the slides. The correlation R-value was shown in
the Correlation & Scatter Plot sheet (Figure 2) which
showed the difference between untreated and treated
arrays.Figure 3 Real-time PCR to verify the disregulated miRNAs
founded in Caski, Hela and Siha groups.Validation of miRNA expression
These miRNAs whose expression was significantly
dysregulated based on microarray analysis were selected
for confirmation by qRT-PCR. Methylation of let-7a has
been reported before (Lu L, et al., [9]), so it was chosen
as control. We found that miR-432, miR-1286, miR-641,
miR-1290, miR-1287 and miR-95 were highly upregulated
just in cells with HPV infection upon 5-AZA treatment,
whereas miR-625 was significantly downregulated (P<0.05)
(Figure 3). Therefore, the analysis of selected miRNAs by
qPCR confirmed the microarray results.
MiR-641, miR-1287 and miR-95 changing most signifi-
cantly in cell lines were chosen for further study in cer-
vical tissue. Methylation status in cervical cancer tissuewere performed with MeDIP-qPCR assay (Figure 4)
compared with adjacent normal tissue. Interestingly,
expression of miR-641 and miR-1287 in cervical tissue was
lower than control, while miR-95 was higher (P<0.05).
Figure 4 Methylation status of disregulated miRNAs in cervical
cancer tissue were performed with MeDIP-qPCR assay.
Calculation of the MeDIP gene of interest/input gene of interest
ratios was based on the fluorescence emission intensity values.
Black bars denote the calculated cutoff values.
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MicroRNA (miRNA) is a novel class of short non-
coding RNA molecules regulating a wide range of cellu-
lar functions through translational repression of their
target genes. DNA methylation is one of the heritable
epigenetic modifications, repressing gene expressions
and consequent phenotypic alterations without changing
the DNA sequence. Recently, epigenetic dysregulation of
tumor suppressor miRNA genes by promoter DNA
methylation has been implicated in human cancers.
In our previous study, we found miR-21 is significantly
overexpressed in human cervical squamous cancer tis-
sues and cell lines. We also proved that miR-21 is in-
volved in cervical squamous cell tumorigenesis by
CCL20 (Yao T, et al., [10]). 5-Aza-CdR which can reacti-
vate the expression of methylated tumor suppressor
genes, is a pyrimidine nucleoside analog that forms a co-
valent complex with DNMT during DNA replication
(Yao TT, et al., [11]). To evaluate if an aberrant DNA
methylation pattern could also contribute to the altered
miRNA expression characterizing the cervical carci-
noma, we analyzed the miRNA profiling of the cervicalcancer cell lines before and after treatment with 5-AZA.
Resulting from our analyses, a number of miRNAs were
over-expressed but not reported, as well as down-
modulated but not deleted. The involvement of an epi-
genetic regulatory mechanism could actually exert a role
on miRNA expression in human cervical cancer.
It is conceivable that several disregulated miRNAs
with no defined functions at this point may exhibit
tumor suppressor or oncogene activity and normally
target components of key signaling pathways that pro-
mote and maintain the growth and survival of cells. Se-
veral analysis revealed high expression level of miR-432
which remained significant as independent predictor for
recurrence-free (RFS) of hepatocellular carcinoma (Huang
YH, et al., [12]). However, in human pituitary GH aden-
omas, miR-432 plays a role as tumor suppressor gene by
regulating HMGA2 (D’Angelo D, et al., [13]).
Thirteen miRNAs including of miR-1286 were
deregulated in both two esophageal carcinoma cell lines
(one adenocarcinoma and one squamous cell carcinoma)
treated with cisplatin or 5-fluorouracil for 24 or 72 h
(Hummel R, et al., [14]). Analysis of predicted targets
of it highlighted molecular networks included functions
such as ‘Cell death’, ‘Cell cycle’, ‘Cellular growth and proli-
feration’, ‘DNA replication, recombination, and repair’
and ‘Drug metabolism’. Cisplatin or 5-fluorouracil altered
miRNA expression in esophageal cancer cells. Ingenuity
Pathway Analysis (IPA) suggested that miR-1286 may
target molecular pathways involved in cell survival after
chemotherapy.
Until recently, there has been just one report about
miR-641 up-regulated in normal chondrocytes (Díaz-
Prado S, et al., [15]). In silico, analyses predicted that key
molecular pathways potentially altered by miRNAs dif-
ferentially expressed in normal and OA chondrocytes in-
clude TGF-beta, Wnt, Erb and mTOR signalling; all of
them implicated in the development, maintenance and
destruction of articular cartilage. We concluded the up-
modulation of miR-641 in our study may also have rela-
tionship with these signaling.
Researches on miR-1290 have been referred on tumor
therapy. Following in vitro photodynamic treatment,
miR-1290 was overexpressed in human epidermoid car-
cinoma cells (A431) (Bach D, et al., [16]). Up-regulation
of microRNA-1290 impairs cytokinesis and affects the
reprogramming of colon cancer cells (Wu J, et al., [17]).
In light of these reports and our results, we proposed
miR-1290-based therapeutic approaches could be deve-
loped in future.
Wilcoxon sign-rank test for paired samples analysis re-
vealed that abnormal miRNAs showed a higher level of vari-
ation across different breast cancer samples. Most of these
miRNAs were significantly down-regulated in tumor sam-
ples, but miR-1287 was consistently expressed in tumor
Yao et al. Virology Journal 2013, 10:175 Page 6 of 7
http://www.virologyj.com/content/10/1/175tissues and serum samples (Guo L, et al., [18]). In follicular
lymphoma, it was increased (Wang W, et al., [19]).
MiR-95 has been shown to be involved in carcino-
genesis. A highly characterized example is pancreatic
cancer, in which miR-95 was confirmed significantly
increasing cell proliferation, invasion, migration and
inhibited cell apoptosis in vitro and in vivo when
compared with negative control (Li WG, et al., [20]).
Concordant changes were also revealed in colorectal
carcinoma (Huang Z, et al., [21]) and pancreatic can-
cer (Zhang Y, et al., [22]). However in head and neck
cancers, miR-95 has been suggested downregulated
(Nurul-Syakima AM, et al., [23]). In HeLa cells, inhi-
bition of miR-95 caused a decrease in cell growth
(Cheng AM, et al., [24]).
In our study, we found miR-625 was decreased after
demethylation. Increasing evidence points to a central
role of miR-625 for vesicle trafficking processes in
oncogenesis and tumor suppression. Expression of
miR-625 is significantly down-regulated and negatively
correlated with lymph node metastasis in gastric can-
cer. MiR-625 significantly inhibits invasion and metas-
tasis of gastric cancer cells both in vitro and in vivo.
ILK is a direct target gene for miR-625 and knock-
down of ILK has a phenocopy of overexpression of
miR-625 (Wang M, et al., [25]). In the hormonal treatment
of endometrial carcinoma, Hec1A cells were treated with
medroxyprogesterone acetate, the expression levels of miR-
625 was increased by more than 400% (Bae J, et al., [26]).
The methlyation DNA immunoprecipitation-based
chip analysis (MeDIP-chip) is a novel high- throughput
array-based method using a monoclonal antibody against
5-methycytidine for the enrichment of the methylated
DNA fragments and then hybridizing to the promoter and
CpG islands of the entire human genome (Zhang Z, et al.,
[27]). Our study found that the contents of promoter
methylation in miR-641 and miR-1287 were inversely cor-
related with the expression levels of these genes in cells
treated with 5-aza-2’-deoxycytidine. Contradictorily, our
results showed that after treatment of 5-AZA, miR-95 was
significantly up-regulated in cell lines, whereas the expres-
sion of it was lower in cervical cancer than normal tissues.
We proposed there may be some other factors coexisted.
However, these different human miRNAs were not
found in microarray of C33A. So, we concluded that the
downregulation may have relationship with the negative
expression of HPV in C33A. It is intriguing to speculate
that the expression of cellular miRNA genes at or near
HPV integration sites may contribute to the tumor pheno-
type.The involvement of an epigenetic regulatory mecha-
nism could actually exert a role on miRNA expression in
cervical cancer. Apparently, our findings may provide new
insights into understanding the pathogenesis of cervical
cancer.Additional files
Additional file 1: Table S1. Primers of real-time PCR.
Additional file 2: Table S2. Primers of Medip-qPCR.
Additional file 3: Table S3. The up-regulated microRNAs after 5-Aza
treatment.
Additional file 4: Table S4. The down-regulated microRNAs after 5-Aza
treatment.
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